Elanco Raises 2026 Outlook After Q2 Growth Led by Zenrelia and Credelio Quattro
Aug 5, 2026, 6:29 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Positive earnings beat/slightly above expectations on revenue, margin, and a clear guidance raise. The Salient drivers include Zenrelia and Credelio Quattro, the AHV acquisition, and a path to sub-3x leverage, all of which support higher multiple expectations and potential near-term upside as investors reprice growth and capital allocation optionality.
AI summary
What happened, with direct paths to the underlying reporting
Elanco posted a strong Q2 with revenue of $1.368B, up 10% YoY and 8% organic CC, driven by Zenrelia and Credelio Quattro. The company lifted full-year guidance and highlighted faster margin expansion along with debt deleveraging, targeting a net leverage below 3x by 2027. The AHV International acquisition, completed in April 2026, supports near-term revenue growth and IPP strategy execution.
Q2 2026 revenue $1,368M, up 10% YoY; organic CC up 8%.
Zenrelia and Credelio Quattro drive growth; AHV acquisition closed in April 2026.
Adj EBITDA $1.01–$1.035B; Adj EPS $1.10–$1.16; leverage ~3.0x by 2027.
Net leverage at 3.1x; management targets below 3x next year.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Jim Cramer's Lightning Round highlighted ELAN as his preferred pick in animal health, potentially sparking renewed investor interest. The endorsement comes alongside Zoetis' leade…
Elanco Animal Health exceeded Q1 earnings expectations with adjusted earnings of 40 cents, driven by robust sales growth and expanding guidance for the full year. The company’s po…
Jim Cramer recommended buying Elanco for its positive turnaround. Barclays initiated coverage with an Overweight rating and $30 price target. Elanco shares have seen a recent 1.8%…
Elanco outlined a focused strategy for sustainable growth at Investor Day. Projected $1 billion free cash flow from 2026 to 2028 supports expansion. Progress towards USDA approval…